ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting

    A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures

    Grant Cannon1, Wei Chen 1, JIncheng Shen 2, Neil Accortt 3, David Collier 4 and Brian Sauer 1, 1Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 2Univeristy of Utah, Salt Lake City, UT, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
  • Abstract Number: 1803 • 2019 ACR/ARP Annual Meeting

    Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina

    Rodrigo Garcia Salinas1, Maria Alicia Lazaro 2, Santiago Scarafia 3, Alejandra Cusa 2, Nieves Capozzi 4, Luciana Casalla 4, Lucia Zarate 4, Maria de la Vega 5, Maria Correa 6, Gustavo Casado 7, Silvia Papasidero 8, Oscar Rillo 9, Nevil Alejandro Muñoz 10, Mariana Benegas 11, Karin Kirmayr 12, Maria Paula Girard Bosch 13, Maria Victoria Martire 14 and Ramiro Gomez 15, 1Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, 2IARI, Buenos Aires, 3Hospital Municipal "San Cayetano", Buenos Aires, Buenos Aires, Argentina, 4Hospital Posadas, Buenos Aires, 5CEIM Investigaciones Medicas, Buenos Aires, Argentina, 6Consultorios Reumatológicos Pampa, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Hospital Militar Central, Buenos Aires, 8Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 9Hospital Pirovano, Buenos Aires, 10Hospital Ramos Mejia, Buenos Aires, 11Sanatorio Mendez, Buenos Aires, 12Hospital Zonal Bariloche, Bariloche, 13Instituto Médico Platense, La Plata, 14Hospital San Martín. Instituto Médico Platense, La Plata, 15Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: The biologics therapies in rheumatoid arthritis (RA) implies a well-known risk of infection. It is of utterly importance to count with predictive models to…
  • Abstract Number: 2301 • 2019 ACR/ARP Annual Meeting

    Profile of Renal Function in Patient Suffering from Rheumatoid Arthritis

    Denis Choquette1, Louis Bessette 2, Loïc Choquette Sauvageau 3, Isabelle Ferdinand 3, Boulos Haraoui 3, Frédéric Massicotte 3, Jean-Pierre Pelletier 4, Jean-Pierre Raynauld 5, Marie-Anaïs Rémillard 3, Diane Sauvageau 3, Edith Villeneuve 6 and Louis Coupal 3, 1Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, 2Centre de l'Ostéoporose et de Rhumatologie de Québec, Québec, QC, Canada, 3Institut de Recherche en Rhumatologie de Montréal, Montréal, QC, Canada, 4University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 5Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 6Institut de Recherche en Rhumatologie de Montréal, Montreal, QC, Canada

    Background/Purpose: Many medications used in the treatment of rheumatoid arthritis (RA) impact renal function. Some of these may be contraindicated in the presence of a…
  • Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting

    Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study

    Xanthe ME Matthijssen1, Ellis Niemantsverdriet 2, Thomas Huizinga 2 and Annette van der Helm-van Mil 3, 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…
  • Abstract Number: 89 • 2019 ACR/ARP Annual Meeting

    Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis

    Ximei Zhang1, Julie Wang 2, Nancy Olsen 3, Wael Jarjour 4 and Song Guo Zheng 4, 1Ohio State College of Medicine, Columbus, 2Ohio State University, columbus, 3Penn State University, Hershey, PA, 4Ohio State College of Medicine, Columbus, OH

    Background/Purpose: Enhanced evidence supports that autoimmune diseases often result from an imbalance between regulatory T cells (Tregs) and interleukin-17-producing T helper (Th17) cells. However, under…
  • Abstract Number: 522 • 2019 ACR/ARP Annual Meeting

    Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis

    Thierry Sornasse1, Jeremy Sokolove 1 and Iain McInnes 2, 1AbbVie Immunology Clinical Development, Redwood City, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
  • Abstract Number: 980 • 2019 ACR/ARP Annual Meeting

    Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis

    Ana Igea 1, Tiago Carvalheiro 2, Beatriz Malvar Fernandez 2, Angela Rodriguez-Trillo 3, Trudy McGarry 4, Carmen Conde 5, Douglas Veale 6, Ursula Fearon 7, Africa Gonzalez 1, Timothy R.D. Radstake 8, Kris A. Reedquist 2 and Samuel Garcia9, 1Department of Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain, 2Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands, 3laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS)-Hospital Clinico (CHUS), Santiago de Compostela, Spain, 4Department of Molecular Rheumatology, Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland, 5Laboratorio de Reumatología Experimental y Observacional, y Servicio de Reumatología, Instituto de Investigacion Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain, 6EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, 7Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, 8Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, 9Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Spain

    Background/Purpose: The semaphorin family is a large group of proteins initially described in axon guidance. However, semaphorins also play a role in other processes involved…
  • Abstract Number: 1365 • 2019 ACR/ARP Annual Meeting

    Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States

    Clifton Bingham1, Shelly Kafka 2, Shawn Black 3, Stephen Xu 4 and Jeffrey Curtis 5, 1Johns Hopkins University, Baltimore, MD, 2Janssen Scientific Affairs, LLC, Horsham, PA, 3Janssen Scientific Affairs, LLC, Horsham, RI, 4Janssen Research & Development, LLC, Spring House, PA, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Use of PROs to assess health-related quality of life in clinical practice, research studies, and clinical trials in Rheumatoid Arthritis (RA) remains an ongoing…
  • Abstract Number: 1945 • 2019 ACR/ARP Annual Meeting

    Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients

    Ankita Singh1, Harikrishnan Nair 2, Vikas Gupta 2, Pradeepta Sekhar 2, Ramnath Misra 3 and Amita Aggarwal 4, 1Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Methotrexate (MTX) is first line therapy to treat rheumatoid arthritis (RA) patients. However, the response is variable with 50-60% showing response and this variability…
  • Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting

    Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico

    Mariangelí Arroyo-Ávila1, Ruth Fred-Jiménez 1, Naydi Pérez-Ríos 1, Noelia Rodríguez 1, Grissel Ríos 1 and Luis Vilá 1, 1University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
  • Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting

    Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs

    Mark Genovese1, Kenneth Kalunian 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, YingMeei Tan 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, Kurt de Vlam 6, David Walker 7 and Tsutomu Takeuchi 8, 1Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 7Northumbria Healthcare, Northumbria, United Kingdom, 8Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
  • Abstract Number: 100 • 2019 ACR/ARP Annual Meeting

    Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells

    Ye Chen1, Julie Wang 2, Nancy Olsen 3, Wael Jarjour 4 and Song Guo Zheng 4, 1Ohio State University, Columbus, OH, 2Ohio State University, columbus, 3Penn State University, Hershey, PA, 4Ohio State College of Medicine, Columbus, OH

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that cannot be cured and current approaches have some severe side effects. Although the pathogenesis is…
  • Abstract Number: 524 • 2019 ACR/ARP Annual Meeting

    A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies

    Joel Kremer1, Filip Van den Bosch 2, Andrea Rubbert-Roth 3, Sebastiao Radominski 4, Gerd Burmester 5, Heidi Camp 6, Sebastian Meerwein 7, Mark Howard 8, Yanna Song 9, Sheng Zhong 10 and Bernard Combe 11, 1Albany Medical College, Albany, NY, 2Ghent University Hospital, Ghent, Belgium, 3Kantonsspital St. Gallen, St Gallen, Switzerland, 4Universidade Federal do Paraná, Curitiba, Brazil, 5Charité—University Medicine Berlin, Berlin, Germany, 6AbbVie Inc., North Chicago, IL, 7AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 8AbbVie Inc., North Chicago, 9AbbVie Inc., North Chicago, IL, USA, North Chicago, 10AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 11CHU Montpellier, Montpellier University, Montpellier, France

    Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…
  • Abstract Number: 981 • 2019 ACR/ARP Annual Meeting

    Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models

    Hani Manfred Sauermilch1, Marie-Lisa Hülser 1, Carina Schreiyäck 1, Yubin Luo 2, Aline Bozec 2, Georg Schett 3, Ulf Müller-Ladner 4 and Elena Neumann 5, 1Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Giessen, Germany, 2Department Clinic of Medicine 3 - Immunology and Rheumatology, University of Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 4Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, 5Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Giessen, Hessen, Germany

    Background/Purpose: Adipocytokines are bioactive factors mainly produced by adipose tissue and exert many important effects on energy homeostasis as well as immune responses. Osteoarthritis (OA)…
  • Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting

    Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study

    Roy Fleischmann1, Carlo Selmi 2, Miguel Angel González-Gay 3, Hubert van Hoogstraten 4, Owen Hagino 4, Tejasweeni Rajput 5, Gregory St John 6, Frank Buttgereit 7 and Mark Genovese 8, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Humanitas Research Hospital, University of Milan, Milan, Italy, 3Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Sanofi, Bridgewater, NJ, 5Cytel, Mumbai, India, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Charité-Universitätsmedizin Berlin, Berlin, Germany, 8Stanford University, Stanford, CA

    Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
  • « Previous Page
  • 1
  • …
  • 163
  • 164
  • 165
  • 166
  • 167
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology